NASDAQ : JBIO

Jade Biosciences, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 14.24 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 905.63M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Details

NameJade Biosciences, Inc.
SectorHealthcare
IndustryBiotechnology
Employees55
Founded2024
CeoTom Frohlich
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS0080642061
Cusip008064206
Cik0001798749
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Tom FrohlichPresident, Chief Executive Officer and Director
Bradford D. Dahms Ph.D.Chief Financial Officer and Treasurer
Dr. Andrew James King BVMS, D.V.M., Ph.D.President of Research and Development
Elizabeth Balta J.D.Chief Legal Officer and Corporate Secretary
Lori StewartSenior Vice President of People
Jonathan QuickSenior Vice President of Finance
Valerie FauvelleSenior Vice President of Regulatory and Quality
Amy SullivanSenior Vice President of Development Operations
Sandy LewisSenior Vice President, Biometrics and Clinical Strategy
Dr. Edward R. Conner M.D.Chief Medical Officer

Contact

AddressBuilding 23, Suite 105, Waltham, Massachusetts 02453, United States
Phone781 312 3013
Websitehttps://jadebiosciences.com